Impact of Study Design on the Results of Continuation Studies of Antidepressants
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Antidepressant continuation studies have used 2 different designs. In the placebo substitution design, all patients are initially treated with active medication in an open-label fashion, and then treatment responders are randomized to continue with medication or switch to placebo in a double-blind manner. In the extension design, patients are randomized to a double-blind placebo-controlled acute study at the outset, and responders to active treatment and placebo are continued on the treatment to which they initially responded. We hypothesized that the design of antidepressant continuation studies would impact on the likelihood of relapse. In the extension design, there is no change in treatment. Whether patients responded to placebo or medication, the treatment that produced the response is continued. In contrast, in the placebo substitution design, there is an obvious change in treatment protocol upon initiation of the continuation phase. Patients are aware that they initially received active medication, and there is now a chance that they will be switched to placebo. We speculated that the expectation of a continued positive response is lower in patients treated using the placebo substitution design than the extension design and therefore predicted that relapse rates would be higher. We conducted a meta-analysis of antidepressant continuation studies and compared the relapse rates in continuation studies using these 2 different designs. As predicted, for both the active medication and placebo groups, the frequency of relapse was lower in studies using an extension design. We also found that the difference in relapse risk between antidepressants and placebo was greater with the extension design. Thus, the design of continuation studies of antidepressants was associated with the absolute percentage of patients who relapse on both active medication and placebo, as well as estimates of differential relapse risk between antidepressants and placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
Residual symptoms after partial remission: an important outcome in depression
Paykel, E. S., Ramana, R., Cooper, Z., Hayhurst, H., Kerr, J., & Barocka, A. (1995) · Psychological Medicine · doi:10.1017/s0033291700033146 · Cited by 791
Loss of Antidepressant Efficacy During Maintenance Therapy: Possible Mechanisms and Treatments
Byrne, S. E., & Rothschild, A. J. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0602 · Cited by 149
Escitalopram continuation treatment prevents relapse of depressive episodes
Rapaport, M. H., Bose, A., & Zheng, H. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0107 · Cited by 121
Robert, P., Montgomery, S. A., Darcourt, G., Robert, G., Houillon, P., Bouchard, J. M., Tatossian, A., Planche, R., Bourgeois, M., Richou, H., et al. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199503001-00006 · Cited by 85
Extended-release venlafaxine in relapse prevention for patients with major depressive disorder
Simon, J. S., Aguiar, L. M., Kunz, N. R., & Lei, D. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2003.10.004 · Cited by 69
Weihs, K. L., Houser, T. L., Batey, S. R., Ascher, J. A., Bolden-Watson, C., Donahue, R. M. J., & Metz, A. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01317-8 · Cited by 65
Cited by
More treatment but no less depression: The treatment-prevalence paradox
Ormel, J., Hollon, S. D., Kessler, R. C., Cuijpers, P., & Monroe, S. M. (2022) · Clinical Psychology Review · doi:10.1016/j.cpr.2021.102111 · Cited by 213
Hansen, R., Gaynes, B., Thieda, P., Gartlehner, G., Deveaugh-Geiss, A., Krebs, E., & Lohr, K. (2008) · Psychiatric Services · doi:10.1176/ps.2008.59.10.1121 · Cited by 172
Andrews, P. W., Kornstein, S. G., Halberstadt, L. J., Gardner, C. O., & Neale, M. C. (2011) · Frontiers in Psychology · doi:10.3389/fpsyg.2011.00159 · Cited by 107
Möller, H.-J. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802264606 · Cited by 107
“However, defining remission using a HAMD-17 cut-off score of 57 identifies a population of remitters that is as heterogeneous as the population of responders in terms of psychosocial impairment (Zimmerman et al. 2007a,b).”
Deshauer, D., Moher, D., Fergusson, D., Moher, E., Sampson, M., & Grimshaw, J. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.071068 · Cited by 78
Metadata
- Authors
- Zimmerman, M., Posternak, M. A., & Ruggero, C. J.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2007-04
- Volume
- 27
- Issue
- 2
- Pages
- 177-181
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2059485586
- Cited by
- 20
- References
- 7
- FWCI
- 1.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Study Design on the Results of Continuation Studies of Antidepressants. https://app.cochat.ai/papers/10.1097/jcp.0b013e31803308e1
- The paper
- Zimmerman, M., Posternak, M. A., & Ruggero, C. J. (2007). Impact of Study Design on the Results of Continuation Studies of Antidepressants. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e31803308e1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.